PF-Atlas › Clinical Trials › NCT02330549
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected NAFLD
Cenicriviroc 150 mg · Phase 2
Registry ID
NCT02330549
Phase
Phase 2
Status
Completed
Drug / intervention
Cenicriviroc 150 mg
Sponsor
Tobira Therapeutics, Inc.
Start
2015-07-17
About this trial
Cenicriviroc 150 mg is evaluated in NCT02330549, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Tobira Therapeutics, Inc.. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02330549 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.